A Multicentre Phase II Study of AZD1775 Plus Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase of Trial: Phase II
Latest Information Update: 25 May 2017
At a glance
- Drugs AZD-1775 (Primary) ; Carboplatin; Gemcitabine; Paclitaxel
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 07 Jun 2017 Biomarkers information updated
- 21 Mar 2017 Planned End Date changed from 1 Feb 2018 to 30 Apr 2018.
- 21 Mar 2017 Planned primary completion date changed from 1 Feb 2018 to 30 Apr 2018.